| What is RSS feed? | About Us |
 |
 Search Score: 6/10
Source: articles.moneycentral.msn.com --- 6 days ago
Shared Health(R) Clinical Xchange(TM) Increases Practice Efficiency by 17 Percent with Real-time Access to Vital Patient Data REDWOOD SHORES, Calif., Aug. 28 /PRNewswire-FirstCall/ -- News ... Source: hotjobs.yahoo.com --- 25 days ago
... Data flow activities and deliver a quality database in accordance with the Data management project plan RESPONSIBILITIES: " Review and prepare Case Report ... ... Source: www.msnbc.msn.com --- 29 days ago
In the mystifying world of biotechnology, investors need a combination of extraordinary patience, iron insides, and sharp stock-picking skills. You need all of those qualities to be a victor, rather than a victim, in an arcane sector that trips up even some of the most astute investors. ... Source: hotjobs.yahoo.com --- 33 days ago
Clinical <em>Data</em> <em>Analyst</em> Clinical <em>Data</em> <em>Analyst</em> Bryn Mawr ... enter into computerized <em>Data</em> system. Will follow-up weekly with all ... ... Source: www.ncbi.nlm.nih.gov --- 31 days ago
Related Articles Ghostwriters, Data manipulation and dollar diplomacy: how drug companies pull the strings in Clinical research. Ann Emerg Med. 2008 Aug;52(2):137-9 Authors: Berger E PMID: 18672488 [PubMed - in process] ... Source: www.ncbi.nlm.nih.gov --- 22 days ago
Related Articles Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors. Oncologist. 2008 Aug 11; Authors: Dal Lago L, D'Hondt V, Awada A The development of targeted therapies has provided new options for the management of patients with advanced solid tumors. There has been particular interest in agents that target the mitogen-activated protein kinase pathway, which controls tumor growth and survival and promotes angiogenesis. Sorafenib is an oral multikinase inhibitor that has been proven effective as a single-agent therapy in renal cell carcinoma, and there is a strong rationale for investigating its use in combination with other agents. In particular, targeting multiple Raf isoforms with sorafenib may help to overcome resistance to other agents, while the ability of sorafenib to induce apoptosis may increase the cytotoxicity of chemotherapeutic agents. Based on positive results in preclinical studies, further investigation in phase I and II studies has shown potential antitumor activity when sorafenib is combined with cytotoxic agents in different solid tumors, including hepatocellular carcinoma and melanoma. Promising results have been reported in phase I and II studies of sorafenib combined with paclitaxel and carboplatin, with oxaliplatin in gastric and colorectal cancer, with docetaxel in breast cancer, with gemcitabine in ovarian cancer, and with capecitabine in differe ... Source: www.ncbi.nlm.nih.gov --- 5 days ago
Related Articles [Asperger syndrome: evolution of the concept and current Clinical Data] Rev Neurol (Paris). 2008 May;164(5):406-13 Authors: Aussilloux C, Baghdadli A Although Asperger syndrome is described by international classifications as a category of pervasive developmental disorder (PDD), its validity as a specific entity distinct from autistic disorders remains controversial. The syndrome, first described by Hans Asperger, could not be distinguished from high functioning autism (onset, symptoms, outcome...). However, international classifications propose a distinction between the two syndromes based on a delayed onset, the absence of speech delay, the presence of motor disorders and a better outcome in Asperger syndrome. This categorical differentiation is not confirmed by current studies and in the absence of biological markers, no Clinical, neuropsychological or epidemiological criteria makes it possible to distinguish high functioning autism from Asperger syndrome. From a Clinical perspective, it is nevertheless of interest to isolate Asperger syndrome from other autistic disorders to propose specific assessment and therapy. PMID: 18555872 [PubMed - indexed for MEDLINE] ... Source: www.moreover.com --- 32 days ago
Suven Life Sciences Ltd. ... Source: www.ncbi.nlm.nih.gov --- 26 days ago
Related Articles Characterization of arterial wall mechanical behavior and stresses from human Clinical Data. J Biomech. 2008 Aug 4; Authors: Masson I, Boutouyrie P, Laurent S, Humphrey JD, Zidi M This paper demonstrates the feasibility of material identification and wall stress computation for human common carotid arteries based on non-invasive in vivo Clinical Data: dynamical intraluminal pressure measured by applanation tonometry, and medial diameter and intimal-medial thickness measured by high-resolution ultrasound echotracking. The mechanical behavior was quantified assuming an axially pre-stretched, thick-walled, cylindrical artery subjected to dynamical blood pressure and perivascular constraints. The wall was further assumed to be three-dimensional and to consist of a nonlinear, hyperelastic, anisotropic, incompressible material with smooth muscle activity and residual stresses. Mechanical contributions by individual constituents-an elastin-dominated matrix, collagen fibers, and vascular smooth muscle-were accounted for using a previously proposed microstructurally motivated constitutive relation. The in vivo boundary value problem was solved semi-analytically to compute the inner pressure during a mean cardiac cycle. Using a nonlinear least-squares method, optimal model parameters were determined by minimizing differences between computed and measured inner pressures over a mean cardiac cycle. The fit-to-Data from two healthy ... Source: www.ncbi.nlm.nih.gov --- 15 days ago
Related Articles Putting the latest Data into practice: case studies and Clinical considerations in menopausal management. Cleve Clin J Med. 2008 May;75 Suppl 4:S25-33 Authors: McKenzie M, Sikon AL, Thacker HL, Gass M, Hodis HN, Jenkins MR PMID: 18693639 [PubMed - in process] ... Source: www.marketwire.com --- 6 days ago
SOUTH SAN FRANCISCO, CA (MARKET WIRE) Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Data from an ongoing Phase I/II Clinical trial of ispinesib are scheduled to be presented as a poster presentation at the 2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, to be held September 5-7, 2008 at the Hilton Washington in Washington, DC. ... Source: www.businesswire.com --- 5 days ago
PHILADELPHIA, Pa.--(BUSINESS WIRE)--Early, in-ambulance treatment with antiplatelet medicine AGGRASTAT® (tirofiban HCL), in addition to the ... Source: www.businesswire.com --- 29 days ago
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Mi-Co, (www.mi-corporation.com), the mobile Data collection software provider, showed its ... Source: www.marketwire.com --- 4 days ago
LYSAKER, NORWAY--(Marketwire - August 31, 2008) - 31 August, 2008, Lysaker, Norway: Pronova BioPharma ASA ( OSE : PRON.OL ) ("Pronova BioPharma" or the "company") announces that the Phase III outcome trial GISSI-Heart Failure demonstrated that Omacor® reduced mortality and morbidity in patients with congestive heart failure (CHF). Both primary endpoints were met in the 7000 patient trial. The results were presented today at the European Society of Cardiology (ESC) Hot Line session in Munich, Germany. The findings were also published in The Lancet. ... Source: www.businesswire.com --- 2 days ago
SAN FRANCISCO--(BUSINESS WIRE)--ATEL Ventures, a leading provider of secured financing to emerging growth companies, is pleased to announce that Clinical Data, Inc. has entered into an ... Source: www.businesswire.com --- 1 day ago
DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/bf105b/theke ... Source: www.prnewswire.com --- 3 days ago
... Source: www.businesswire.com --- 15 hours ago
DUBLIN, Ireland--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/0d4368/entr ... Source: www.marketwire.com --- 3 days ago
LYSAKER, NORWAY (MARKET WIRE) ... Source: www.medicalnewstoday.com --- 3 days ago
Cytokinetics, Incorporated (NASDAQ: CYTK) announced that Data from an ongoing Phase I/II Clinical trial of ispinesib are scheduled to be presented as a poster presentation at the 2008 American Society of Clinical Oncology (ASCO) Breast Cancer Symposium, to be held September 5-7, 2008 at the Hilton Washington in Washington, DC. ... Find more results for Clinical Data on RSSMicro.com |
Copyright © 2008 RSSMicro.com
